Science Translational Medicine · 2017 · 200 citations · 23 references
Life SciencesPharmacologyPharmacotherapyAutoimmunityImmunopharmacologyImmunotherapyAutoantibodiesAutoantibody-mediated DiseaseAutoimmune Disease ImmunotherapyAutoimmune DiseasesImmunoglobulin FunctionPharmacokinetics Of Monoclonal AntibodiesClinical Pharmacology EvidenceConcentrationFc Neonatal Receptor BindingFc ReceptorsFcrn InhibitionFcrn-mediated RecyclingNeonatal Fc Receptor BindingNeonatal Fc Receptor Recycling
= 1)]. Rozanolixizumab pharmacokinetics demonstrated nonlinear increases with dose. There were sustained dose-dependent reductions in serum IgG concentrations (IV and SC rozanolixizumab). These data provide clinical evidence for the therapeutic potential of rozanolixizumab.
23
Arturo González‐Quintela, Rosario Alende, Francisco Gudé et al. · Clinical & Experimental Immunology · 2007 · 641 citations · Full text
Dose-related patterns of glucocorticoid-induced side effects
Dörte Huscher, K. Thiele, Erika Gromnica‐Ihle et al. · Annals of the Rheumatic Diseases · 2008 · 582 citations